Advanced Search
Contact | Corporate | Help

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Sponsors:
  • New England Retina Associates
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • Choroidal Melanoma
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: Ranibizumab 2 mg
  • Drug: 0.5 mg Ranibizumab
Enrollment:
12

Additional information about NCT01251978.


SourceSolution © 2008-2012